{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-194948","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.362036+00:00","generated_at":"2026-05-17T08:30:45.580491+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Galera Therapeutics reduces Blackstone royalty to 4% from high single-digit on halted products","bullets":["Amendment cuts royalty payable to Blackstone on worldwide net sales of avasopasem/rucosopasem from high single-digit % to 4%.","Reduced rate also applies to Product Payment damages received during the royalty period.","Company has suspended clinical development and commercial readiness for both products.","Purchaser is Blackstone Life Sciences, successor in interest to Clarus Ventures."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-194948","json":"https://secwatch.observer/filing/0001193125-25-194948.json","markdown":"https://secwatch.observer/filing/0001193125-25-194948.md","text":"https://secwatch.observer/filing/0001193125-25-194948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312525194948/0001193125-25-194948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312525194948/d478971d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:30:45.580491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}